ASHINGTON — The budget deal announced in the Senate on Wednesday contained a provision surprising to drug companies and Medicare beneficiaries alike: a sooner-than-expected change to the program’s “donut hole” coverage gap.

The provision included in the budget plan would mean a sizable hit to the pharmaceutical industry. It would move from 2020 to 2019 a requirement that drug makers pick up a larger portion of costs for their medicines for Part D beneficiaries who reach the so-called “donut hole” — a gap in Medicare coverage where beneficiaries often have to pay eye-watering drug prices out of pocket up to a certain dollar amount.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.